VDVikas R. Dharnidharka

Vikas R. Dharnidharka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vikas R. Dharnidharka has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    BEAT-BK: An Adaptive, Randomized Controlled Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Kidney-pancreas Transplantation Recipients (BEAT-BK) Study Protocol

    by Ryan Gately, Michael Dymock, Dharshana Sabanayagam, Scott B. Campbell, Jonathan C. Craig, Vikas Dharnidharka, Anna Francis, Jonathan M. Gleadle, Martin Hajek, Sana Hamilton, et al.

    Background.: BK polyomavirus (BKPyV) is a common opportunistic infection in kidney transplant recipients, typically reactivating in the context of immunosuppression. Although asymptomatic in immunocompetent individuals, reactivation in transplant recipients can cause BKPyV-associated nephropathy (BKPyVAN), a leading cause of graft dysfunction and loss. BKPyV viremia affects approximately 10%–15% of transplant recipients, and once BKPyVAN is established, the risk of graft failure can exceed 50%. The current standard of care involves immunosuppression reduction to restore virus-specific immunity, but this approach increases the risk of acute and chronic rejection. Intravenous immunoglobulin (IVIg), which contains antiviral and immunomodulatory antibodies, has been proposed as an adjunctive therapy, although evidence supporting its efficacy remains limited to small observational studies. Methods.: The BEAT-BK trial is a multicenter, adaptive, randomized controlled trial comparing standard immunosuppression reduction with or without IVIg in kidney and simultaneous pancreas-kidney transplant recipients with BKPyV viremia or biopsy-confirmed BKPyVAN. The trial will enroll participants aged 2 y and older, randomizing them 1:1 to receive standard care alone or in combination with a total IVIg dose of 2 g/kg for 8 wk. An adaptive Bayesian design will permit interim analyses with the potential for early trial success or futility. Results.: The primary endpoint is a composite ordinal outcome at 12 wk, incorporating death, graft loss, estimated glomerular filtration rate decline, acute rejection, viral load, and degree of immunosuppression reduction. Secondary outcomes include viral clearance, development of BKPyVAN and donor-specific antibodies, infections, malignancy, quality of life, and cost-effectiveness. Conclusions.: This trial will provide the first high-quality evidence on the role of IVIg in BKPyV management and inform clinical decision-making in posttransplant care.

  • Open Access

    Tacrolimus IPV Group Membership Does Not Consistently Track With Electronically Monitored or Self-reported Adherence in Adolescent and Young Adult Kidney Transplant Recipients

    by Cyd K. Eaton, Cozumel S. Md Pruette, Kristin A. Riekert, Nazanin Yousefzadeh, Ahna L. Pai, Sandra Md Amaral, Vikas R. Dharnidharka, Bärbel Knäuper, Jodi M. Smith, Susan L. Furth, et al.

    Background.: High intrapatient variability (IPV) of tacrolimus trough concentrations (SD ≥ 2, coefficient of variation (CV%) ≥ 30) is associated with rejection and graft loss and may indicate nonadherence. However, the association between tacrolimus IPV and electronically monitored or self-reported adherence is unknown. Methods.: This secondary analysis of the TAKE-IT (Teen Adherence in Kidney Transplant Effectiveness of Intervention Trial) compared electronically monitored and self-reported adherence between participants with high and low tacrolimus IPV among 103 adolescent and young adult kidney transplant recipients (mean age = 15.18 y, 59% male, 60% White, 65% >1-y posttransplant). Results.: Electronically monitored daily taking and timing adherence were not significantly associated with tacrolimus IPV group in binomial generalized linear mixed effects models: Participants with tacrolimus SD ≥ 2 or CV% ≥ 30 were no less likely to take each daily dose than those below these cutoffs (SD < versus ≥ 2: odds ratio [OR]; 0.84, 95% confidence interval [CI], 0.48-1.47; P = 0.54 and CV% < versus ≥ 30: OR, 0.72; 95% CI, 0.43-1.21; P = 0.22). Participants with tacrolimus SD ≥ 2 or CV% ≥ 30 were no less likely to take each daily dose on time than those below these cutoffs (SD < versus ≥ 2: OR, 0.70; 95% CI, 0.40-1.23; P = 0.21 and CV% < versus ≥ 30: OR, 0.68; 95% CI, 0.40-1.16; P = 0.15). Electronically monitored averages of doses taken, doses taken early/late, and differences from expected dose time were associated with tacrolimus IPV (P < 0.05) but were poor classifiers of IPV group membership (area under the curve < 0.70). Self-reported adherence was not associated with tacrolimus IPV. Conclusions.: Tacrolimus IPV group membership does not consistently track with behavioral adherence measures. Relying on tacrolimus IPV group membership may misidentify nonadherence in adolescent and young adult kidney transplant recipients.